Zobrazeno 1 - 10
of 117
pro vyhledávání: ''
Autor:
Anuradha Sehrawat, Kozue Sakao, Rajiv Dhir, Su-Hyeong Kim, Kumar Chandra-Kuntal, Rachel C. Jankowitz, Jan H. Beumer, Eun-Ryeong Hahm, Julie A. Arlotti, Anna A. Powolny, Joomin Lee, Shivendra V. Singh
Publikováno v:
JNCI Journal of the National Cancer Institute. 104:1228-1239
Novel approaches for chemoprevention of breast cancer are clinically attractive because many risk factors associated with this disease (eg, genetic predisposition, late-age at first full-term pregnancy, early menarche, and late menopause) are not eas
Autor:
Nicole L. Nollen, Lisa Sanderson Cox, Won S. Choi, Babalola Faseru, Jasjit S. Ahluwalia, Neal L. Benowitz, Kolawole S. Okuyemi, Rachel F. Tyndale, Matthew S. Mayo
Publikováno v:
JNCI Journal of the National Cancer Institute. 104:290-298
Results Participants at baseline visit (week 0) smoked an average of 8.0 CPD and had a mean serum cotinine level of 275.8 ng/mL (SD = 155.8 ng/mL); most used menthol cigarettes (83.7%) and smoked within 30 minutes of waking (72.2%). After imputing th
Autor:
Robert A. Figlin, Dongrui R. Lu, Michael S. Baum, Darrel P. Cohen, Martin Gore, Brian I. Rini, Isan Chen, Subramanian Hariharan, Robert J. Motzer
Publikováno v:
Journal of the National Cancer Institute, 103(20), 1557-1557. Oxford University Press
JNCI Journal of the National Cancer Institute
JNCI Journal of the National Cancer Institute
Background Hypertension (HTN) is an on-target effect of the vascular endothelial growth factor pathway inhibitor, sunitinib. We evaluated the association of sunitinib-induced HTN with antitumor efficacy and HTN-associated adverse events in patients w
Autor:
Leyvraz, S., Pampallona, S., Martinelli, G., Ploner, F., Perey, L., Aversa, S., Peters, S., Brunsvig, P., Montes, A., Lange, A., Yilmaz, U., Rosti, G., Marrow, Transplantation
Publikováno v:
Journal of the National Cancer Institute, vol. 100, no. 8, pp. 533-541
BACKGROUND: The dose intensity of chemotherapy can be increased to the highest possible level by early administration of multiple and sequential high-dose cycles supported by transfusion with peripheral blood progenitor cells (PBPCs). A randomized tr
Autor:
Judit Anido, José Baselga, Santiago Ramón y Cajal, Federico Rojo, Serena Di Cosimo, Javier Cortes, Marta Guzman, Maurizio Scaltriti, Alberto Ocaña, Joaquín Arribas, Xavier Matias-Guiu
Publikováno v:
JNCI Journal of the National Cancer Institute. 99:628-638
Background Women with HER2-overexpressing breast cancers have poor prognosis, and many are resistant to the HER2 monoclonal antibody trastuzumab. A subgroup of HER2-overexpressing tumors also express p95HER2, an amino terminally truncated receptor th
Autor:
Xing-Jie Liang, Yuri Kotliarov, Peter McL. Black, Patrick Y. Wen, Dragan Maric, Oluwaseun Akeju, Umberto De Girolami, Wells W. Wu, John K. Park, Jean C. Zenklusen, Teri T.B. Ngo, Wei Zhang, Tien Peng, Neal Jeffries, Sandra Pastorino, Rong Fong Shen, Dong Won Kang, Howard A. Fine
Publikováno v:
JNCI Journal of the National Cancer Institute. 99:639-652
Background Malignant gliomas are generally resistant to all conventional therapies. Notable exceptions are anaplastic oligodendrogliomas with loss of heterozygosity on chromosome 1 p (1p +/- ). Patients with 1p +/- anaplastic oligodendroglioma freque
Autor:
Yaddanapudi Ravindranath, Tanya L. Jensen, Steven Buck, Larry H. Matherly, Ronald Thomas, Jeffrey W. Taub, Mark Stout, Dana Tatman, Yubin Ge
Publikováno v:
JNCI Journal of the National Cancer Institute. 97:226-231
Down syndrome children with acute megakaryocytic leukemia (AMkL) have higher cure rates than non-Down syndrome acute myeloid leukemia (AML) patients treated with cytosine arabinoside (ara-C). Megakaryoblasts from Down syndrome AML patients are more s
Autor:
A. Hay, Paul Vasey, Stan B. Kaye, Hani Gabra, Ronnie Atkinson, Robert E. Coleman, David E. Parkin, Alan N. Gordon, James Paul, Gordon C Jayson
Publikováno v:
JNCI Journal of the National Cancer Institute. 96:1682-1691
BACKGROUND: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the standard of care for treatment of ovarian carcinoma. We compared the combination of docetaxel-carboplatin with the combination of paclitaxel-carboplatin as fir
Autor:
Michael F. Press, Eleonor Quan, Deborah Toppmeyer, Mary Ann Lindsay, Michael Smylie, David M. Reese, Alessandro Riva, Ravi Patel, Wolfgang Eiermann, Pierre Fumoleau, John Crown, Sandra Blitz, Donald W. Northfelt, Dennis J. Slamon, Tadeusz Pienkowski, Mark D. Pegram
Publikováno v:
JNCI Journal of the National Cancer Institute. 96:759-769
Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of California at Los Angeles-Oncology Research Network (UCLA-ORN) a
Autor:
Richard J. Pietras, Dennis J. Slamon, Mark D. Pegram, Carminda O'Callaghan, Gottfried E. Konecny, Malgorzata Beryt
Publikováno v:
JNCI Journal of the National Cancer Institute. 96:739-749
Background: Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2. We characterized interactions between trastuzumab and chemotherapeuti